ArticleCancer medicine2025

Cost-Effectiveness of Pembrolizumab Plus Trastuzumab and Chemotherapy Versus Trastuzumab Plus Chemotherapy as First-Line Treatment of HER2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma in China.

Yifang Liang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.